Table 2.
Number of COVID-19 patients with individual cytokine elevation
| All | Moderate (N = 114) | Severe (N = 54) | Critical (N = 71) | ||||
|---|---|---|---|---|---|---|---|
| Toci | No Toci | Toci | No Toci | Toci | No Toci | ||
| Cytokine | (N = 239) | (N = 39) | (N = 75) | (N = 48) | (N = 6) | (N = 66) | (N = 5) |
| IL-6, No. (%) | 184 (77.0) | 34 (87.2) | 40 (53.3) | 41 (85.4) | 4 (66.7) | 61 (92.4) | 4 (80.0) |
| sIL2R, No. (%) | 121 (50.6) | 17 (43.6) | 26 (34.6) | 26 (54.2) | 3 (50.0) | 48 (72.7) | 1 (20.0) |
| IL-10, No. (%) | 54 (22.6) | 4 (10.3) | 9 (12.0) | 13 (27.1) | 0 (0.0) | 25 (37.9) | 3 (60.0) |
| IFN-Y, No. (%) | 70 (29.3) | 11 (28.2) | 14 (18.7) | 18 (37.5) | 0 (0.0) | 27 (40.9) | 0 (0.0) |
| IL-1 B, No. (%) | 41 (17.2) | 5 (12.8) | 13 (17.3) | 9 (18.8) | 0 (0.0) | 13 (19.7) | 1 (20.0) |
| IL-12, No. (%) | 23 (9.6) | 3 (7.7) | 7 (9.3) | 7 (14.6) | 0 (0.0) | 6 (9.1) | 0 (0.0) |
| IL-13, No. (%) | 10 (4.2) | 1 (2.6) | 2 (2.7) | 2 (4.1) | 0 (0.0) | 5 (7.6) | 0 (0.0) |
| IL-17, No (%) | 34 (14.2) | 3 (7.7) | 14 (18.7) | 5 (10.4) | 0 (0.0) | 10 (15.2) | 2 (40.0) |
| IL-2, No (%) | 60 (25.1) | 11 (28.2) | 15 (20.0) | 14 (29.2) | 0 (0.0) | 19 (28.8) | 1 (20.0) |
| IL-4, No. (%) | 12 (5.0) | 1 (2.5) | 3 (4.0) | 4 (8.3) | 0 (0.0) | 4 (6.1) | 0 (0.0) |
| IL-5, No. (%) | 11 (4.6) | 1 (2.5) | 2 (2.7) | 2 (4.2) | 0 (0.0) | 6 (9.1) | 0 (0.0) |
| IL-8, No. (%) | 17 (7.1) | 3 (7.7) | 1 (1.3) | 2 (4.2) | 0 (0.0) | 11 (16.7) | 0 (0.0) |
| TNF-a, No. (%) | 35 (14.6) | 2 (5.1) | 11 (14.7) | 10 (20.8) | 0 (0.0) | 11 (16.7) | 1 (20.0) |